Why male mice lose anti-cancer immunity earlier than females
Researchers found why male mice lose anti-cancer immunity earlier than females: androgens accelerate thymic involution and push naive CD8+ T cells into virtual memory states that proliferate poorly, depleting the antigen-recognition reserve needed to fight new tumors by middle age. A Massachusetts General Hospital team published the findings in Nature Aging, and restoring thymic activity improved male protection.
Key Takeaways
- Middle-aged male mice controlled implanted melanoma less effectively than middle-aged females; young mice showed no sex gap.
- The disparity tracked to earlier loss of naive CD8+ T cells and smaller lymph nodes in males, not weaker antigen presentation.
- Androgen suppression restored thymic cellularity, naive T cell numbers, and tumor control in middle-aged males.
- Human imaging and blood datasets hinted at similar sex-biased thymic and naive CD8+ decline with age.
What did the mouse cancer experiments show?
When researchers implanted melanoma into young and middle-aged mice, tumor growth looked similar in young males and females. By middle age, males controlled tumors less effectively than females.
Depleting CD8+ T cells sped tumor growth in both sexes and erased the female advantage, tying the gap to this killer T cell type. Middle-aged females had more tumor-specific, activated CD8+ cells inside tumors. You can follow related longevity immune research in our Longevity & Biohacking hub.
Why do male mice lose naive T cell reserves sooner?
Lymph nodes—not the spleen—drove the stronger female response. Female tumor-draining nodes held more activated, tumor-specific CD8+ cells without faster proliferation or better antigen presentation. The bottleneck was supply: absolute naive CD8+ counts fell with age, and male mice started losing them earlier.
Males also skewed earlier toward “virtual memory” cells—naive T cells that adopt a memory-like state without matching antigen. Those cells released more cytokines after stimulation but expanded less well and showed more senescence-linked gene expression. Brief IL-15 treatment that boosted virtual memory in young females later left them with fewer naive CD8+ cells and weaker tumor control.
Can restoring the thymus close the sex gap?
The thymus, where T cells mature, involutes faster in males. After immune depletion, middle-aged females rebuilt naive CD8+ pools faster and showed more recent thymic emigrants. Removing the thymus at six weeks wiped out the female advantage in middle-age melanoma control.
Because androgens suppress thymic activity, researchers cut androgen signaling via castration or degarelix. That increased thymic cellularity, repopulated lymph nodes, restored naive CD8+ numbers, and improved melanoma control in middle-aged males, substantially shrinking the sex difference. Coverage of the study is available from Lifespan.io, which summarized the Nature Aging paper amid a busy month of rejuvenation research noted in its October 2026 Rejuvenation Roundup.
The work does not prove clinical therapies for men. It does map a hormone–thymus–naive T cell pathway that may help explain why some cancer rates diverge by sex around midlife.